RESUMEN
OBJECTIVE: Current treatment options for Allergic Rhinitis (AR) may have their own limitations and side effects. This study aimed to investigate the effects of Ma-al-Shaeer (MS), a novel natural formulation based on Hordeum vulgare, in the treatment of AR compared with Fexofenadine (FX). METHODS: A total of 77 patients with AR were divided into two groups: MS group (n=38) and FX group (n=39). The first group received 15 g of dried MS powder, and the second group received 60 mg of FX twice daily for 14 days. At baseline (week zero) and after the 14-day treatment period (week two), both groups were evaluated for sneezing, rhinorrhea, nasal congestion, nasal itching, post nasal drip, eye, throat, or ear symptoms, headache, cough, mental function, quality of life scores, blood eosinophil count and total IgE levels. Rhinitis control assessment tests were conducted at week zero and again at one week after cessation of treatment (week three) in both groups. RESULTS: All symptoms of AR except cough were significantly reduced in both groups; for nasal congestion, post nasal drip, and headache, the MS treatment was found to be superior. Rhinitis control was significantly increased after treatment in both groups (p value < 0.001). Both drugs significantly reduced total IgE levels. There was no significant change in eosinophil count in either group. CONCLUSION: MS formulation based on H. vulgare may be an effective treatment for AR. Further studies are needed to confirm the effect of MS as an alternative treatment in AR.
Asunto(s)
Antialérgicos/uso terapéutico , Antagonistas de los Receptores Histamínicos H1 no Sedantes/uso terapéutico , Hordeum , Extractos Vegetales/uso terapéutico , Rinitis Alérgica/tratamiento farmacológico , Terfenadina/análogos & derivados , Adolescente , Adulto , Anciano , Antialérgicos/efectos adversos , Antialérgicos/aislamiento & purificación , Biomarcadores/sangre , Niño , Femenino , Antagonistas de los Receptores Histamínicos H1 no Sedantes/efectos adversos , Hordeum/química , Humanos , Inmunoglobulina E/sangre , Irán , Masculino , Persona de Mediana Edad , Extractos Vegetales/efectos adversos , Extractos Vegetales/aislamiento & purificación , Rinitis Alérgica/diagnóstico , Rinitis Alérgica/inmunología , Semillas , Terfenadina/efectos adversos , Terfenadina/uso terapéutico , Factores de Tiempo , Resultado del Tratamiento , Adulto JovenRESUMEN
BACKGROUND: Solar urticaria (SU) is a rare photodermatosis causing a significant impact on patients' quality of life (QoL), and treatment is often challenging. AIM: To analyse clinical experience with a tailored stepwise therapeutic approach. METHODS: A retrospective cohort design was used. Patients with suspected SU underwent laboratory investigations and photoprovocation. Those with a high minimal urticaria dose (MUD) were treated with a single antihistamine (protocol 1), and those with a lower MUD received three types of antihistamines (protocol 2); both protocols included a leucotriene receptor antagonist (LRA). In cases of failure, treatment was switched to omalizumab at doses of < 300 mg/month with incremental dosage increases as necessary (monthly dose range, 150-600 mg/month). Symptom relief and photoprovocation under treatment were evaluated. RESULTS: In total, 30 patients (10 men, 20 women) were enrolled. Most (87%) were sensitive to visible light (1-70 J/cm2 ) with or without extension to ultraviolet A. Of the 30 patients, 23 opted for our stepwise approach: 22 achieved complete remission on protocols 1 or 2 (n = 17) or after switching to omalizumab (n = 5), and another patient achieved partial remission under omalizumab. There were no treatment-related severe adverse effects. CONCLUSIONS: Symptoms of SU can be well controlled by treatment with antihistamines and an LRA tailored to the degree of photosensitivity, followed by omalizumab in refractory cases. This has important implications for patient QoL.
Asunto(s)
Antialérgicos/uso terapéutico , Antagonistas de los Receptores Histamínicos/uso terapéutico , Antagonistas de Leucotrieno/uso terapéutico , Omalizumab/uso terapéutico , Trastornos por Fotosensibilidad/tratamiento farmacológico , Urticaria/tratamiento farmacológico , Acetatos/uso terapéutico , Adolescente , Adulto , Anciano , Cetirizina/uso terapéutico , Niño , Estudios de Cohortes , Ciclopropanos , Manejo de la Enfermedad , Femenino , Humanos , Loratadina/análogos & derivados , Loratadina/uso terapéutico , Masculino , Persona de Mediana Edad , Quinolinas/uso terapéutico , Estudios Retrospectivos , Sulfuros , Terfenadina/análogos & derivados , Terfenadina/uso terapéutico , Adulto JovenRESUMEN
BACKGROUND: Solar urticarial (SU) is characterized by erythema, whealing, and/or pruritus occurring minutes after sun exposure. Treatment is difficult and often unsatisfactory. OBJECTIVES: To determine the action spectra and minimal urticaria dose (MUD) and to tailor a treatment regimen graded according to disease severity in a series of patients with SU. PATIENTS AND METHODS: Eleven patients (seven females, four males, age range: 5-60 years) with a clinical history suggestive of SU, verified by photo-provocation tests to ultraviolet A (UVA), visible light, and/or UVB, were treated with various combinations of antihistamines and leukotriene receptor antagonist. RESULTS: All patients were sensitive to visible light (median MUD 50 J/cm(2)). Three patients were sensitive to UVA (median MUD 3.75 J/cm(2)), and one patient was sensitive to UVB (MUD of 0.03 J/cm(2)). Two patients experienced a spontaneous remission without treatment. One patient declined treatment. The remaining eight patients were managed by a combination of antihistamines (desloratidine, fexofenadine, cetirizine HCl) and a leukotriene receptor antagonist (montelukast). Seven of the 8 patients experienced a sustained remission of symptoms and signs following treatment. CONCLUSIONS: Photoprovocation for SU with determination of action spectra and MUD enables specifically tailored treatment regimens consisting of combinations of antihistamines and leukotriene receptor antagonist.
Asunto(s)
Acetatos/uso terapéutico , Antagonistas de los Receptores Histamínicos H1 no Sedantes/uso terapéutico , Antagonistas de Leucotrieno/uso terapéutico , Trastornos por Fotosensibilidad/tratamiento farmacológico , Quinolinas/uso terapéutico , Luz Solar/efectos adversos , Urticaria/tratamiento farmacológico , Adolescente , Adulto , Cetirizina/uso terapéutico , Niño , Preescolar , Ciclopropanos , Quimioterapia Combinada , Femenino , Humanos , Loratadina/análogos & derivados , Loratadina/uso terapéutico , Masculino , Persona de Mediana Edad , Trastornos por Fotosensibilidad/etiología , Inducción de Remisión , Remisión Espontánea , Índice de Severidad de la Enfermedad , Sulfuros , Terfenadina/análogos & derivados , Terfenadina/uso terapéutico , Rayos Ultravioleta/efectos adversos , Urticaria/etiología , Adulto JovenRESUMEN
Environmental challenge chambers (ECC) have been used to expose people to pollen allergens within a stable atmosphere and to examine the efficacy of treatment. Although pollinosis is one of the typical IgE-mediated type I allergic diseases, allergic inflammation is thought to contribute to the fundamental pathogenesis and prophylactic treatment may reduce exacerbations of pollinosis. The purpose of this study was to compare the efficacy of prophylactic treatment with nasal steroid (mometasone furoate nasal spray) or an antihistamine (fexofenadine) in the control of cedar pollinosis using the ECC. In a randomized, double-blind two-way crossover study, 48 patients received nasal steroid or antihistamine for 7 consecutive days (days 1-7). On day 8, patients were exposed to cedar pollen (8000 grains/m(3)) in the ECC for 3 hours. Nasal symptoms induced by pollen exposure were assessed. Total nasal symptom scores (TNSSs) during the exposure in the ECC were not significantly different between the antihistamine and the nasal steroid groups. Nasal symptoms induced by pollen exposure using the ECC persisted for up to 3 days. TNSSs after pollen exposure on days 8-11 were significantly lower in the nasal steroid group compared with the antihistamine group. Prophylactic treatment with nasal steroid is more effective than antihistamine against pollinosis, particularly in the late phase. Clinical trial registration JAPIC CTI 101182 (www.clinicaltrials.jp/user/ctiMain_e.jsp).
Asunto(s)
Antialérgicos/uso terapéutico , Antagonistas de los Receptores Histamínicos/uso terapéutico , Pregnadienodioles/uso terapéutico , Rinitis Alérgica Estacional/prevención & control , Terfenadina/análogos & derivados , Administración Intranasal , Adolescente , Adulto , Alérgenos/inmunología , Antialérgicos/administración & dosificación , Cedrus/inmunología , Quimioprevención , Estudios Cruzados , Método Doble Ciego , Femenino , Antagonistas de los Receptores Histamínicos/administración & dosificación , Humanos , Masculino , Persona de Mediana Edad , Furoato de Mometasona , Polen/efectos adversos , Polen/inmunología , Pregnadienodioles/administración & dosificación , Rinitis Alérgica Estacional/tratamiento farmacológico , Rinitis Alérgica Estacional/etiología , Índice de Severidad de la Enfermedad , Terfenadina/administración & dosificación , Terfenadina/uso terapéutico , Resultado del Tratamiento , Adulto JovenRESUMEN
BACKGROUND: Clara cell 10-kD protein (CC10) is well known to be an immuno-suppressive protein secreted from airway epithelial cells after inflammatory stimulation and is involved in the development of allergic disorders. Although histamine H1 receptor antagonists are used for the treatment of allergic disorders, the influence of the agents on CC10 production is not well understood. In the present study, we examined the influence of a histamine H1 receptor antagonist, fexofenadine hydrochloride (FEX) on CC10 production in vitro and in vivo. METHODS: Nasal epithelial cells (5 x 10(6) cells/ml) were stimulated with 20 ng/ml TNF-alpha in the presence of various concentrations of FEX for 24 hours. CC10 levels in culture supernatants were examined by ELISA. Patients with Japanese cedar pollinosis were treated orally with FEX twice a day at a single dose of 60 mg for two weeks during Japanese cedar pollen season (February 2011 to April 2011). CC10 levels in nasal secretions were also examined by ELISA. RESULTS: The addition of FEX into cell cultures caused increase in CC10 production induced by TNF-alpha stimulation, and the minimum concentration that caused significant increase was 200 ng/ml. Oral administration of FEX also increased CC10 levels in nasal secretions from pollinosis patients along with attenuation of clinical symptoms. CONCLUSION: The ability of FEX to enhance CC10 production may account, at least in part, for the clinical efficacy of the agent in allergic disorders, including allergic rhinitis.
Asunto(s)
Células Epiteliales/inmunología , Antagonistas de los Receptores Histamínicos H1/uso terapéutico , Cavidad Nasal/inmunología , Rinitis Alérgica Estacional/tratamiento farmacológico , Terfenadina/análogos & derivados , Uteroglobina/biosíntesis , Adulto , Células Cultivadas , Cryptomeria/inmunología , Ensayo de Inmunoadsorción Enzimática , Células Epiteliales/citología , Células Epiteliales/efectos de los fármacos , Antagonistas de los Receptores Histamínicos H1/farmacología , Humanos , Masculino , Persona de Mediana Edad , Cavidad Nasal/citología , Cavidad Nasal/efectos de los fármacos , Polen/inmunología , Rinitis Alérgica Estacional/inmunología , Rinitis Alérgica Estacional/patología , Índice de Severidad de la Enfermedad , Terfenadina/farmacología , Terfenadina/uso terapéutico , Factor de Necrosis Tumoral alfa/farmacología , Uteroglobina/inmunología , Uteroglobina/metabolismoRESUMEN
CONCLUSIONS: These findings suggest that the down-regulation of interleukin (IL)-5 gene expression in collaboration with the suppression of histamine H(1) receptor (H1R) gene expression in the nasal mucosa provides the basis for better therapeutic effects of preseasonal prophylactic treatment with antihistamines in patients with seasonal allergic rhinitis caused by Japanese cedar pollen. OBJECTIVES: The effects of prophylactic administration of antihistamines on the expression of IL-5 and IL-33 mRNA in the nasal mucosa of the patients with pollinosis were investigated. METHODS: Eight patients had already visited the hospital before the peak pollen period and started preseasonal prophylactic treatment with antihistamines. Seventeen patients who first visited the hospital during the peak pollen period were designated as the no treatment group. After local anesthesia, nasal mucosa was obtained by scraping the inferior concha with a small spatula during the peak pollen period. RESULTS: During the peak pollen period, the expression of IL-5 mRNA, but not that of IL-33 mRNA, in the nasal mucosa of patients receiving preseasonal prophylactic treatment with antihistamines was significantly lower in comparison with that of patients without treatment. Moreover, there was a significant correlation between the expression of IL-5 mRNA and the nasal symptoms or the expression of H1R mRNA.
Asunto(s)
Antagonistas de los Receptores Histamínicos/uso terapéutico , Interleucina-5/metabolismo , Interleucinas/metabolismo , Mucosa Nasal/metabolismo , Rinitis Alérgica Estacional/prevención & control , Butirofenonas/farmacología , Butirofenonas/uso terapéutico , Cryptomeria/inmunología , Femenino , Antagonistas de los Receptores Histamínicos/farmacología , Humanos , Interleucina-33 , Masculino , Persona de Mediana Edad , Mucosa Nasal/efectos de los fármacos , Mucosa Nasal/inmunología , Piperidinas/farmacología , Piperidinas/uso terapéutico , Polen/inmunología , Terfenadina/análogos & derivados , Terfenadina/farmacología , Terfenadina/uso terapéuticoRESUMEN
BACKGROUND: In Japan, oral antihistamines are frequently used as the initial treatment for seasonal allergic rhinitis (SAR), and intranasal steroids are added when nasal symptoms worsen. This study aimed to evaluate whether starting treatment with fluticasone propionate nasal spray (FP) from the beginning of pollinosis symptoms and adding fexofenadine hydrochloride tablet (FEX) when SAR is aggravated could achieve improved amelioration of nasal symptoms throughout the pollen season in comparison with a treatment that involves starting with FEX and later adding FP. METHODS: In this pragmatic, randomized, open-label, parallel-group trial, 51 Japanese cedar pollinosis patients (age, 16-85 years) were randomly divided and administered FP 100 mcg twice daily as an initial drug with FEX 60 mg twice daily as an additional drug and the same treatment in the reverse order. Nasal symptoms were evaluated in a daily dairy using a 4-point scale. The primary outcome was area under curve of the line representing the daily total nasal symptom score in the pollen season on a graph. RESULTS: Initial treatment with FP was significantly (P = 0.0015) more effective than initial treatment with FEX in improving the primary outcome. The average daily total nasal symptom score in the initial treatment with FP group was better than that in the initial treatment with FEX group throughout the pollen season. CONCLUSIONS: Initiating treatment with FP and adding FEX might lead to improved outcomes for nasal symptoms in comparison with the same drugs administered in the reverse order.
Asunto(s)
Androstadienos/administración & dosificación , Antialérgicos/administración & dosificación , Rinitis Alérgica Estacional/tratamiento farmacológico , Terfenadina/análogos & derivados , Adulto , Androstadienos/efectos adversos , Androstadienos/uso terapéutico , Antialérgicos/efectos adversos , Antialérgicos/uso terapéutico , Femenino , Fluticasona , Humanos , Masculino , Persona de Mediana Edad , Rociadores Nasales , Polen , Comprimidos , Terfenadina/administración & dosificación , Terfenadina/efectos adversos , Terfenadina/uso terapéutico , Resultado del TratamientoRESUMEN
We recently showed that intranasal phototherapy represents an efficient therapeutic modality for the treatment of patients with seasonal allergic rhinitis (SAR). The aim of this pilot study was to compare the efficacy of intranasal phototherapy with that of the new generation antihistamine fexofenadine HCl in SAR. A randomized open study was conducted in patients with a history of moderate-to-severe ragweed-induced SAR. Thirty-one patients were randomly assigned to receive either intranasal irradiation three times a week for 2 weeks, or 180 mg fexofenadine HCl per day for 2 weeks. Each patient kept a diary of symptoms for nasal obstruction, nasal itching, rhinorrhea, sneezing and palate itching. Total nasal score (TNS), a sum of scores for nasal symptoms, was also calculated. In the rhinophototherapy group the individual scores significantly decreased compared with baseline for all of the parameters. In the fexofenadine HCl group none of the scores improved significantly at the end of the treatment except sneezing. TNS was significantly decreased in the rhinophototherapy group, but no significant change was observed in the fexofenadine HCl group after 2 weeks of treatment. In conclusion, we found that intranasal phototherapy is more efficient than fexofenadine HCl in reducing clinical symptoms for SAR.
Asunto(s)
Antialérgicos/uso terapéutico , Fototerapia , Rinitis Alérgica Estacional/tratamiento farmacológico , Terfenadina/análogos & derivados , Administración Intranasal , Adolescente , Adulto , Ambrosia/inmunología , Antialérgicos/administración & dosificación , Femenino , Humanos , Masculino , Persona de Mediana Edad , Fototerapia/normas , Proyectos Piloto , Terfenadina/administración & dosificación , Terfenadina/uso terapéuticoRESUMEN
BACKGROUND: Recent studies have suggested that allergic rhinitis is closely related to bronchial asthma, reflecting the "one airway-one disease" hypothesis. It is unclear if the effects of pranlukast, a leukotriene-receptor antagonist, are consistent with this hypothesis. OBJECTIVE: The goal of the study was to determine if pranlukast has effects on the upper and lower airways through a comparison of the effects of fexofenadine and pranlukast on airway hyperresponsiveness in non-asthmatic patients with cedar pollinosis before the Japanese cedar pollen season and during the peak pollen season. METHODS: Patients received fexofenadine hydrochloride plus oral mequitazine (fexofenadine group) or pranlukast hydrate plus oral mequitazine (pranlukast group) as an initial treatment. Subsequent changes in airway responsiveness to acetylcholine were measured. RESULTS: Among patients in whom coughing developed during the peak pollen season, airway responsiveness significantly increased in the fexofenadine group. In the pranlukast group, airway responsiveness did not increase significantly, regardless of the presence or absence of coughing. CONCLUSIONS: The results indicate that pranlukast hydrate inhibits airway hyperresponsiveness in non-asthmatic patients with Japanese cedar pollinosis. In turn, this suggests that cysteinyl leukotrienes have a role in increased airway responsiveness.
Asunto(s)
Asma , Hiperreactividad Bronquial/tratamiento farmacológico , Cromonas/uso terapéutico , Cryptomeria/inmunología , Rinitis Alérgica Estacional/tratamiento farmacológico , Acetilcolina/farmacología , Actividades Cotidianas , Adulto , Antialérgicos/administración & dosificación , Antialérgicos/uso terapéutico , Antiasmáticos/administración & dosificación , Antiasmáticos/uso terapéutico , Antígenos de Plantas/inmunología , Hiperreactividad Bronquial/inmunología , Hiperreactividad Bronquial/fisiopatología , Pruebas de Provocación Bronquial , Broncoconstricción/efectos de los fármacos , Broncoconstricción/fisiología , Chamaecyparis/inmunología , Cromonas/administración & dosificación , Tos/diagnóstico , Tos/prevención & control , Eosinófilos/patología , Femenino , Volumen Espiratorio Forzado/efectos de los fármacos , Volumen Espiratorio Forzado/fisiología , Humanos , Inmunoglobulina E/sangre , Inmunoglobulina E/inmunología , Masculino , Persona de Mediana Edad , Mucosa Nasal/efectos de los fármacos , Mucosa Nasal/patología , Fenotiazinas/administración & dosificación , Fenotiazinas/uso terapéutico , Polen/inmunología , Rinitis Alérgica Estacional/inmunología , Rinitis Alérgica Estacional/fisiopatología , Terfenadina/administración & dosificación , Terfenadina/análogos & derivados , Terfenadina/uso terapéutico , Resultado del Tratamiento , Adulto JovenRESUMEN
In Japan, information on daily Japanese cedar pollen counts is made public during pollen season. If symptom severity and treatment outcome are predictable according to these pollen counts, management of seasonal allergic rhinitis may become more precise. The aims of the study were to evaluate the relationship between airborne pollen counts, symptom severity and treatment outcome in Japanese cedar pollinosis patients. In the randomized study, patients with moderate to most severe Japanese pollinosis were treated with fexofenadine (60 mg BD) or fexofenadine and nasal corticosteroids for 2 weeks. During the same period daily airborne pollen counts were measured. A total of 105 adult patients were enrolled. No difference of treatment efficacy was seen among groups. Detailed results of efficacy and safety were previously described elsewhere. In univariate analysis, the mean cumulative amount of airborne pollen exposure for 4 days prior to the study tended to affect symptom severity (P = 0.053) and the mean cumulative amount of airborne pollen during the treatment period tended to show difference among five treatment outcome categories (P = 0.066). In multivariate analysis, the mean cumulative amount of airborne pollen exposure for 4 days prior to the study was identified as the only significant factor of symptom severity (P = 0.0327) and cumulative amount of airborne pollen during the treatment period (P = 0.027) and allergic history (P = 0.027) were significant factors of treatment outcomes. No serious adverse effect was reported during the study. The amount of airborne pollen may be predictive of both symptom severity and treatment outcome.
Asunto(s)
Aire , Antialérgicos/uso terapéutico , Cryptomeria , Polen/efectos adversos , Rinitis Alérgica Estacional/tratamiento farmacológico , Rinitis Alérgica Estacional/etiología , Terfenadina/análogos & derivados , Adulto , Antiinflamatorios/uso terapéutico , Femenino , Humanos , Masculino , Estudios Prospectivos , Rinitis Alérgica Estacional/diagnóstico , Rinitis Alérgica Estacional/inmunología , Índice de Severidad de la Enfermedad , Terfenadina/uso terapéuticoRESUMEN
BACKGROUND: Symptomatic dermographism is the most common type of physical urticaria. It can be severe and poorly controlled with H1 antihistamines in some patients. Photochemotherapy (psoralen plus ultraviolet [UV] A) may help the itch of dermographism but the effect of narrowband (NB) UVB therapy has not been previously studied. OBJECTIVES: We sought to examine the clinical efficacy of NB UVB therapy for itch and whealing in symptomatic dermographism and to assess the duration of the effect during 3 months of follow-up. METHODS: Eight patients (6 female) were enrolled into an open uncontrolled prospective study. Intensity of itching and whealing was assessed with visual analog scales and the whealing response was evaluated by testing with a dermographometer at pressures of 20, 36, and 60 g/mm2 on the upper aspect of the back. NB UVB phototherapy was given for 6 weeks 3 times weekly starting at 50% of minimal erythema dose with 20% to 0% increments as tolerated. Fexofenadine (180 mg/d) was taken during the run-in period and subsequently throughout the study and follow-up as required. Patients were followed for 3 months with regular assessments every 6 weeks after completion of phototherapy. RESULTS: All patients showed an improvement in itching at the end of NB UVB treatment (mean [SD] reduction 52.3% [31.6%]). Subjective assessment of whealing revealed a significant improvement in all but two patients (mean [SD] reduction 71% [54%]). There was a small and statistically significant improvement in cumulative dermographometer-induced wheal widths at the end of phototherapy (P = .038). A time trend for the relapse of symptoms within 12 and 18 weeks after completing phototherapy was significant for both visual analog scale scores but not for dermographometer-induced whealing. LIMITATIONS: The apparent rarity of antihistamine-resistant symptomatic dermographism limited the study to a small number of participants. The severity of the condition did not permit a controlled and blinded study design. CONCLUSIONS: NB UVB phototherapy is an effective second-line treatment for patients with severe symptomatic dermographism responding poorly to fexofenadine. This therapy can lead to subjective relief of pruritus and whealing and objective reduction of whealing. NB UVB phototherapy may restore symptom control with antihistamines in some patients.
Asunto(s)
Terapia Ultravioleta/métodos , Urticaria/radioterapia , Adulto , Resistencia a Medicamentos , Femenino , Antagonistas de los Receptores Histamínicos H1/uso terapéutico , Humanos , Masculino , Proyectos Piloto , Estudios Prospectivos , Prurito/radioterapia , Terfenadina/análogos & derivados , Terfenadina/uso terapéuticoRESUMEN
Corticosteroids and 5-aminosalicylic acid are the primary standard therapy for inflammatory bowel disease. Recent immunologic data implicate an involvement of mast cell activation followed by increased histamine secretion and elevated tissue concentrations of histamine in the pathogenesis of ulcerative colitis. In the present case, the clinical course of a 35-year-old man with steroid-dependent chronic active ulcerative colitis, who did not respond to high-dose steroids, antibiotics, or azathioprine during 3 years, is reported. Clinical disease activity and established serological markers were recorded during 6 weeks of unsuccessful therapy and during the next 6 weeks, as a new nonsedative antihistaminergic drug, a mast cell stabilizer, and an hypoallergenic diet were implemented in addition to conventional therapy. Induction of remission was achieved within 2 weeks after treatment with fexofenadine, disodium cromoglycate, and an amino acid-based formula. Clinical disease activity, stool frequency, leukocytes, c-reactive protein, and orosomucoid levels in serum decreased rapidly. Daily steroid administration could be gradually reduced along with 6 weeks of this treatment. This report suggests that histamine and mast cell activity may be important pathophysiological factors responsible for persistent clinical and mucosal inflammatory activity in ulcerative colitis despite the use of steroids. In ulcerative colitis, patients unresponsive to conventional treatment, therapeutic considerations should also include an antiallergic approach when further signs of atopy or intestinal hypersensitivity are present.
Asunto(s)
Aminoácidos/uso terapéutico , Colitis Ulcerosa/tratamiento farmacológico , Cromolin Sódico/uso terapéutico , Glucocorticoides/uso terapéutico , Antagonistas de los Receptores Histamínicos H1 no Sedantes/uso terapéutico , Terfenadina/análogos & derivados , Administración Oral , Adulto , Antiasmáticos/administración & dosificación , Antiasmáticos/uso terapéutico , Biopsia , Colitis Ulcerosa/patología , Colonoscopía , Quimioterapia Combinada , Estudios de Seguimiento , Antagonistas de los Receptores Histamínicos H1 no Sedantes/administración & dosificación , Humanos , Masculino , Inducción de Remisión , Terfenadina/uso terapéuticoRESUMEN
BACKGROUND: Allergen-specific immunotherapy, although not a cure, remains the only treatment available that can alter the natural course of an allergic disease. However, the risk of allergen specific immunotherapy-related systemic reactions (SRs), reported to occur in approximately 1% to 14% of patients and which can range from mild to fatal in seriousness, represents a barrier to implementing this unique and effective treatment option. OBJECTIVE: To explore the possibility that pretreatment with the H1-antihistamine fexofenadine could prevent the occurrence of severe SRs induced by immunotherapy in Japanese patients with allergic rhinitis. METHODS: In this open-label, multicenter study, 134 patients receiving immunotherapy for allergic rhinitis were randomized 1:1 to a group receiving pretreatment with fexofenadine hydrochloride (60 mg) 2 hours before immunization injection (n = 67) or to a control group receiving no pretreatment (n = 67). Patients were further grouped into those who received cedar pollen immunotherapy and those who received dust mite immunotherapy. RESULTS: Pretreatment with fexofenadine 2 hours before immunotherapy significantly reduced the occurrence of severe SRs (P = .03), significantly increased the proportion of patients receiving cedar pollen immunotherapy who achieved the target maintenance dose (TMD) (P = .03), and significantly reduced the length of time to attain the TMD (P = .047 and P = .003 for patients receiving cedar pollen and dust mite immunotherapy, respectively). CONCLUSIONS: This study suggests a novel role for fexofenadine in enhancing the safety of immunotherapy and increasing the proportion of patients achieving the TMD.
Asunto(s)
Desensibilización Inmunológica , Antagonistas de los Receptores Histamínicos H1/administración & dosificación , Rinitis Alérgica Perenne/terapia , Rinitis Alérgica Estacional/terapia , Terfenadina/análogos & derivados , Adulto , Antialérgicos/administración & dosificación , Antialérgicos/uso terapéutico , Cedrus/inmunología , Dermatophagoides farinae/inmunología , Femenino , Antagonistas de los Receptores Histamínicos H1/uso terapéutico , Humanos , Masculino , Estudios Multicéntricos como Asunto , Polen/inmunología , Rinitis Alérgica Perenne/tratamiento farmacológico , Rinitis Alérgica Estacional/tratamiento farmacológico , Terfenadina/administración & dosificación , Terfenadina/uso terapéuticoRESUMEN
In a previous study, cetirizine and fexofenadine similarly relieved seasonal allergic rhinitis symptoms in the first 5 hours, but cetirizine was more effective at 21-24 hours postdose. This randomized, double-blind, placebo-controlled study compared the response to treatment between 5 and 12 hours. Eligible ragweed allergic subjects were exposed to pollen in the Environmental Exposure Unit and randomized (n = 599) to a single dose of cetirizine, 10 mg; fexofenadine, 180 mg; or placebo (2.5:2.5:1). The primary efficacy end point was the change from baseline in total symptom severity complex (TSSC) score at 12 hours postdose. TSSC score was the sum of self-rated scores (0 = absent to 3 = severe) for runny nose, sneezing, itchy nose/palate/throat, and itchy/watery eyes, recorded half-hourly. Mean baseline TSSC scores were similar: 9.2, cetirizine and fexofenadine; 8.9, placebo. Reductions in TSSC scores from baseline were 4.3 at 12 hours and 5.0 overall (i.e., average over 5-12 hours postdose) for cetirizine and 3.4 and 4.4, respectively, for fexofenadine. Cetirizine produced a 26% greater reduction in TSSC at 12 hours (p = 0.001) and 14% greater reduction in TSSC overall (p = 0.006) compared with fexofenadine. Cetirizine and fexofenadine reduced TSSC scores (p < 0.001) and individual symptoms (p < 0.05) more than placebo. However, cetirizine was more effective than fexofenadine (p < 0.05) for runny nose and sneezing (12 hours and overall), itchy/watery eyes (12 hours), and itchy nose/throat/palate (overall). Incidence of treatment-emergent adverse events and somnolence were similar among groups: cetirizine, 25.3 and 0.8%, respectively; fexofenadine, 29.6 and 0%, respectively; placebo, 35.0 and 0%, respectively. In conclusion, cetirizine produced greater relief of seasonal allergic rhinitis symptoms than fexofenadine at 12 hours postdose and over the 5- to 12-hour postdose period.
Asunto(s)
Antialérgicos/uso terapéutico , Cetirizina/uso terapéutico , Antagonistas de los Receptores Histamínicos H1/uso terapéutico , Rinitis Alérgica Estacional/tratamiento farmacológico , Terfenadina/análogos & derivados , Adolescente , Adulto , Anciano , Alérgenos , Antialérgicos/efectos adversos , Cetirizina/efectos adversos , Método Doble Ciego , Femenino , Antagonistas de los Receptores Histamínicos H1/efectos adversos , Humanos , Masculino , Persona de Mediana Edad , Polen , Rinitis Alérgica Estacional/diagnóstico , Terfenadina/efectos adversos , Terfenadina/uso terapéuticoRESUMEN
Comparisons of the efficacy, onset and duration of action of fexofenadine and montelukast are limited. This study evaluated the pharmacodynamic properties of these agents in an allergen-induced wheal-and-flare model. This randomized, placebo-controlled, crossover study was composed of three treatment periods and two visits on consecutive days for each period, with each period separated by a 14-day (+/-4) washout. At each treatment visit, subjects received a predose allergen skin-prick test followed by either a single dose of fexofenadine HCl 180 mg, montelukast sodium 10 mg, or placebo. Allergen skin-prick testing was performed at 20, 40, and 60 minutes, then hourly through 12 hours and at 23 hours and 24 hours postdose. Adults (n = 48) with positive skin-prick tests were included in the analysis. Significant flare inhibition occurred from 40 minutes through 24 hours postdose for fexofenadine versus placebo (p < 0.05), whereas montelukast did not reach statistical significance for flare inhibition at any time point compared with placebo. Significant wheal inhibition occurred from 60 minutes through 24 hours postdose for fexofenadine versus placebo (p = 0.0012); montelukast did not significantly suppress wheal versus placebo at any time point. Fexofenadine had greater suppression than montelukast for both wheal and flare from 40 minutes through 24 hours (p < .05). Maximum suppression of flare and wheal reached 79.0 and 72.3% for fexofenadine, and 7.3 and 9.6% for montelukast. Fexofenadine suppressed the allergen-induced wheal-and-flare response to a significantly greater extent, and had a significantly faster onset of action, compared with montelukast.
Asunto(s)
Acetatos/uso terapéutico , Antagonistas de los Receptores Histamínicos H1/uso terapéutico , Antagonistas de Leucotrieno/uso terapéutico , Quinolinas/uso terapéutico , Terfenadina/análogos & derivados , Urticaria/prevención & control , Adolescente , Adulto , Alérgenos/efectos adversos , Ambrosia/efectos adversos , Estudios Cruzados , Ciclopropanos , Femenino , Humanos , Masculino , Persona de Mediana Edad , Poaceae/efectos adversos , Polen/efectos adversos , Sulfuros , Terfenadina/uso terapéutico , Árboles/efectos adversos , Urticaria/etiologíaAsunto(s)
Efedrina/uso terapéutico , Hipersensibilidad/tratamiento farmacológico , Terfenadina/análogos & derivados , Terfenadina/uso terapéutico , Publicidad , Alérgenos/efectos adversos , Antialérgicos/uso terapéutico , Antagonistas de los Receptores Histamínicos H1/uso terapéutico , Humanos , Descongestionantes Nasales/uso terapéutico , Plantas/inmunología , Asunción de RiesgosRESUMEN
BACKGROUND: Japanese cedar pollinosis, a common disease with morbidity of approximately 20% in the Japanese population, is characterized by subjectively irritating symptoms during an annual 3-month period. OBJECTIVE: To investigate the effectiveness of cetirizine hydrochloride, loratadine, and fexofenadine hydrochloride in reducing pollinosis symptoms induced while walking in a park during the pollen season. METHODS: A randomized, double-masked, placebo-controlled trial was conducted in 113 individuals with Japanese cedar pollinosis during 2 days in March 2003 in Osaka Expo Park, Osaka, Japan. Participants (aged 20-57 years) were divided into 4 groups according to treatment assignment: cetirizine hydrochloride, 10 mg/d; fexofenadine hydrochloride, 120 mg/d; loratadine, 10 mg/d; and placebo (lactose), twice daily. Symptoms were recorded hourly during the study. Furthermore, all the patients completed the Japanese version of the Rhinoconjunctivitis Quality of Life Questionnaire before and after the trial. RESULTS: Self-evaluated symptom scores in all 3 active treatment groups showed significant improvements compared with the placebo group. Furthermore, the cetirizine group showed significant improvement in the domains of frequency of nose blowing and nasal obstruction compared with placebo. In addition, improvement in Japanese Rhinoconjunctivitis Quality of Life Questionnaire scores was higher in the cetirizine group than in the loratadine and placebo groups. CONCLUSION: Cetirizine seems to be more effective than fexofenadine and loratadine at reducing subjective symptoms in this study population.
Asunto(s)
Cryptomeria/inmunología , Antagonistas de los Receptores Histamínicos H1 no Sedantes/uso terapéutico , Polen/inmunología , Rinitis Alérgica Estacional/tratamiento farmacológico , Terfenadina/análogos & derivados , Adulto , Cetirizina/uso terapéutico , Método Doble Ciego , Esquema de Medicación , Femenino , Humanos , Japón , Loratadina/uso terapéutico , Masculino , Persona de Mediana Edad , Calidad de Vida , Rinitis Alérgica Estacional/inmunología , Estornudo/efectos de los fármacos , Encuestas y Cuestionarios , Terfenadina/uso terapéuticoRESUMEN
BACKGROUND: Although currently in its infancy, quality of life (QOL) research in Japan is rapidly expanding and is expected to become a standard outcome measure in clinical trials. In Japan, QOL has not previously been assessed in patients with allergic rhinitis (AR); we report the first clinical study applying the recently validated Japanese translations of the Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) and Work Productivity and Activity Impairment-Allergy Specific (WPAI-AS) Questionnaire to assess the effects of the oral antihistamine, fexofenadine, on QOL and work productivity due to cedar pollinosis. PATIENTS AND METHODS: A randomized, double-blind, placebo-controlled, single-site study was conducted during the peak cedar pollinosis season in Japan. After a 7-day run-in period, subjects were randomized to receive fexofenadine HCl 60 mg twice daily (bid) or placebo for 2 weeks. RESULTS: Overall, 206 Japanese subjects with AR were included in the intention-to- treat population (fexofenadine, n = 104, and placebo, n = 102). Fexofenadine statistically significantly improved overall QOL compared with placebo (p = 0.005) and improvements were reported in the RQLQ domains: activities (p = 0.047), practical problems (p = 0.003), nasal symptoms (p = 0.003) and eye symptoms (p = 0.001). Clinically significant improvements in practical problems, eye symptoms and activity limitations, exceeding the 0.05 level, were observed with fexofenadine. These improvements in QOL were associated with significant symptom relief (p < 0.001 vs. placebo). Improvements in impairment at work were also reported with fexofenadine. CONCLUSION: In Japan, this is the first clinical study to show that fexofenadine HCl (60 mg b.i.d.) improves overall QOL and work productivity in patients with seasonal AR using validated Japanese instruments.
Asunto(s)
Alérgenos , Antagonistas de los Receptores Histamínicos H1/uso terapéutico , Polen , Rinitis Alérgica Estacional/tratamiento farmacológico , Terfenadina/análogos & derivados , Terfenadina/uso terapéutico , Adulto , Cryptomeria/inmunología , Método Doble Ciego , Eficiencia , Femenino , Humanos , Japón , Masculino , Calidad de Vida , Rinitis Alérgica Estacional/inmunología , Resultado del TratamientoRESUMEN
Although antihistamine-decongestant combinations are frequently used for allergic rhinitis, published data about the onset of action of these combination agents are limited. This randomized, double-blind, placebo-controlled, parallel-group study investigated the onset of action, efficacy, and safety of fexofenadine HCl 60 mg/pseudoephedrine HCl 120 mg or placebo in patients with moderate-to-severe seasonal allergic rhinitis in an allergen exposure unit. Assessments included major symptom complex (MSC) score (sum of sneezing, itchy nose, runny nose, watery eyes, itchy eyes, itchy ears/throat, and stuffy nose), and total symptom complex (TSC) score (MSC symptoms plus nose blows, sniffles, postnasal drip, and cough). Onset of action was defined as the first time that two consecutive, statistically significant absolute changes in MSC scores from baseline were achieved for study drug relative to placebo. The onset of action for the combination was 60 minutes (mean absolute MSC change from baseline: -6.9 +/- 0.3 for the combination compared with -5.9 +/- 0.3 for placebo from a baseline of 17.0 and 16.8, respectively; p < 0.05) for the modified intention-to-treat population (n = 486). Reductions in absolute MSC scores were significantly greater with the combination than placebo at all subsequent time points (p < 0.01). The combination resulted in significantly greater reductions compared with placebo for percent MSC, absolute TSC, and percent TSC scores at 60 minutes postdose (all p < 0.05) and throughout the study (all p < 0.05). The incidence of adverse events was 1.6 and 3.3% for the combination and placebo, respectively. In conclusion, fexofenadine HCl 60 mg/pseudoephedrine HCl 120 mg is effective in the treatment of patients with moderate-to-severe seasonal AR, with an onset of action of 60 minutes and a good safety profile.
Asunto(s)
Broncodilatadores/farmacología , Efedrina/farmacología , Antagonistas de los Receptores Histamínicos H1/farmacología , Rinitis Alérgica Estacional/tratamiento farmacológico , Terfenadina/análogos & derivados , Terfenadina/farmacología , Adolescente , Adulto , Alérgenos/inmunología , Ambrosia/inmunología , Pruebas de Provocación Bronquial , Broncodilatadores/efectos adversos , Broncodilatadores/uso terapéutico , Niño , Método Doble Ciego , Combinación de Medicamentos , Efedrina/efectos adversos , Efedrina/uso terapéutico , Femenino , Antagonistas de los Receptores Histamínicos H1/efectos adversos , Antagonistas de los Receptores Histamínicos H1/uso terapéutico , Humanos , Masculino , Persona de Mediana Edad , Polen/inmunología , Rinitis Alérgica Estacional/etiología , Terfenadina/efectos adversos , Terfenadina/uso terapéutico , Factores de Tiempo , Resultado del TratamientoRESUMEN
Allergen specific nasal challenge (ASNC) is an optimal model to study the pathophysiological mechanisms sustaining allergic inflammation, particularly the cytokine pattern. Antihistamines have been accepted as a highly effective therapy for allergic rhinitis. The aim of this double blind, randomised, placebo controlled study was the evaluation of symptoms and cytokines, during the early phase, after a single dose of mizolastine (10 mg), fexofenadine (120 mg) or placebo, using the model of ASNC. A total of 30 patients with allergic rhinitis underwent nasal challenge 6 hours after treatment. The following parameters were evaluated 30 minutes after ASNC (i.e. early phase): nasal symptoms (rhinorrhea, itching, sneezing, obstruction), and cytokine pattern, including IL1, IL6, and TNFalpha. Mizolastine was associated with early phase reduction of: i) clinical symptoms (p < 0.03), ii) cyotkine levels of IL1 (p = 0.003), IL6 (p < 0.007), and TNF_ (p < 0.003) in comparison with placebo group. Fexofenadine significantly inhibited IL6 (p < 0.004) and TNFalpha (p < 0.004) levels in comparison with placebo. The present findings demonstrate that mizolastine exerts a significant effect on early phase events, reducing symptoms and pro-inflammatory cytokines. Fexofenadine reduces TNFalpha and IL6 levels only. These effects appear to be clinical relevant for mizolastine.